The coronary 5-HT1B-like receptor has been implicated in vasospasm and it is postulated that a 5-HT1B-like antagonist may block the detrimental action of 5-HT whilst not interfering with normal blood vessel function. The synthesis and pharmacological profile of a novel series of 2-(N-heteroaryl)carboxamido-5-substituted-N,N-dimethyltryptamine derivatives as silent (as judged by the inability of angiotensin II to unmask 5-HT1B-like receptor mediated agonist activity in the rabbit femoral artery), competitive and selective 5-HT1B-like receptor antagonists is described. Modifications to the 2-carboxamido sidechain as well as the 5-ethylene linked heterocycle are explored. N-Furfuryl-5-[2-(N-phthalimido)ethyl]-3-[2-(dimethylamino)ethyl]-1H-indole-2-carboxamide (34) was discovered which fulfilled our in vitro selection criteria and which had a favourable pharmacokinetic profile. Compound 34 showed good affinity (pKB = 7.38) for the vascular 5-HT1B-like receptor and greater than 125 fold selectivity over α1-adrenoceptor affinity. The selectivity of 34 and related compounds for the 5-HT1B-like receptor over other receptor subtypes is discussed and a mode of binding for this class of compound to a pharmacophore model is proposed.
冠状动脉5-HT1B样受体与血管痉挛有关,并且推测5-HT1B样拮抗剂可以阻断5-HT的有害作用,同时不干扰正常的血管功能。一系列新型 2-(N-杂芳基)甲酰
氨基-5-取代-
N,N-二甲基色胺衍
生物的合成和药理学概况为沉默(通过
血管紧张素 II 无法揭露 5-HT1B 样受体介导的激动剂来判断)描述了竞争性和选择性 5-HT1B 样受体拮抗剂。探索了对 2-甲酰胺基侧链以及 5-亚乙基连接的杂环的修饰。发现 N-糠基-5-[2-(N-邻苯二甲
酰亚胺)乙基]-3-[2-(
二甲氨基)乙基]-1H-
吲哚-2-甲酰胺 (34),它满足我们的体外选择标准,并且具有良好的药代动力学特征。化合物 34 对血管 5-HT1B 样受体表现出良好的亲和力 (pKB = 7.38),选择性比 α1-
肾上腺素受体亲和力高 125 倍以上。讨论了 34 种及相关化合物相对于其他受体亚型对 5-HT1B 样受体的选择性,并提出了此类化合物与药效团模型的结合模式。